1. Home
  2. Press release
Feb 24, 2010 15:48 JST

Source: Eisai

Eisai Launches REVOVIR(R) in the Philippines for the Treatment of Chronic Hepatitis B

TOKYO, Feb 24, 2010 - (ACN Newswire) - Eisai Co., Ltd. announced today that the Company's Philippine subsidiary, HI-Eisai Pharmaceutical Inc., launched "REVOVIR(R) 30mg Capsules" (generic name: clevudine) in the Philippines for the treatment of chronic hepatitis B.

REVOVIR is a Nucleoside Reverse Transcriptase Inhibitor (NRTI). It exerts anti-hepatitis B virus (HBV) effects by inhibiting DNA polymerase, the enzyme that is necessary for the virus to replicate. Clinical studies have shown that a once-daily oral dose of REVOVIR not only reduces the amount of HBV DNA, but also normalises alanine aminotransferase (ALT) levels in patients experiencing deterioration in liver function caused by chronic hepatitis B.

REVOVIR was approved in the Philippines in February 2009 and it is indicated for the inhibition of virus replication in chronic hepatitis B patients (HBeAg-positive or HBeAg-negative) with evidence of active viral replication and elevations in serum aminotransferases.

It is estimated that approximately 1.7 million people suffer from chronic hepatitis B in the Philippines. However, there are many patients who are unable to receive diagnosis and medical attention or who find it difficult to continue treatment due to a lack of awareness of the disease or their own economic circumstances. Eisai will strive to fulfil its commitment as a human health care (hhc) company to bring this new treatment to as many of these patients as possible at affordable prices and to contribute to the treatment of patients with chronic hepatitis B in the Philippines.

Eisai obtained the exclusive rights to develop, market, and manufacture clevudine in eight Asian countries from Bukwang Pharma, a South Korean pharmaceutical company, and the development of the compound is ongoing in these countries with the exception of the Philippines. A Phase III clinical trial of clevudine has been initiated in China and marketing authorisation applications have been submitted in India, Indonesia, Malaysia, and Thailand.

Eisai considers hepatic disease as a therapeutic area of focus in China and other Asian countries and thus markets and develops drugs such as hepatic disease/allergic disease agents Stronger Neo-Minophagen C(R) and Glycyron(R) Tablets as well as branched-chain amino acid formula Livact(R) Granules. Through these efforts, Eisai will continue to make further contributions to increasing the benefits to patients with hepatic disease across Asia.


Contact:
Eisai Co., Ltd.
Public Relations Department
Tel. +81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Latest Press Release


Mitsubishi Shipbuilding Receives Order for an Offshore Patrol Vessel from the Indonesian Maritime Security Agency
Jan 30, 2025 12:35 JST

Fujitsu and Asepeyo collaborate to modernise the management of occupational benefits and contingencies
Jan 30, 2025 11:56 JST

Suzuki, Daihatsu, and Toyota Decide on the Release Schedule for Mini-Commercial Van Electric Vehicles
Jan 30, 2025 10:56 JST

A Quantum Leap into Uplisting: Spectral Capital and the Next Generation of Computing
Jan 29, 2025 22:47 JST

NEC combines video analysis technology with generative AI to generate advice for improving work quality
Jan 29, 2025 10:08 JST

Japan's Telecommunications Carriers Strengthen Disaster Response by Conducting Joint Training for Shared Refueling Stations
Jan 28, 2025 17:39 JST

FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 28, 2025 09:46 JST

Ogier's milestone Monte win crowns TOYOTA GAZOO Racing one-two
Jan 27, 2025 17:24 JST

Anime Tokyo Station: Let's Enjoy together!! History of Anime Series "OSHI NO KO"
Jan 27, 2025 13:00 JST

hootfolio, Inc., a Provider of Causal Analysis Technology, Launches Business Development
Jan 27, 2025 12:01 JST

Sustainable Shared Transport and Fujitsu launch open platform for joint transportation and delivery in Japan, enhancing logistics efficiency across industries
Jan 27, 2025 10:53 JST

DOCOMO to Exhibit at MWC Barcelona 2025, World's Largest Connectivity Exhibition
Jan 24, 2025 17:39 JST

Hitachi Launches Food Quality Visualization Solution with Time-Temperature Sensing Ink
Jan 24, 2025 12:40 JST

Mitsubishi Heavy Industries Aero Engines and Rolls-Royce Celebrate 20 Years of Collaboration
Jan 24, 2025 10:38 JST

World's First Successful Transmission of Huge Volume Mission Data Using 1.5 micron Optical Inter-Satellite Communication
Jan 24, 2025 09:19 JST

TANAKA PRECIOUS METAL TECHNOLOGIES Develops AgSn TLP Sheet, a Sheet-type Bonding Material for Power Semiconductors
Jan 23, 2025 11:00 JST

MHI Receives Order for 3 New Series Trainsets (12 Cars) for Seibu Railway's Yamaguchi Line
Jan 22, 2025 17:27 JST

Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
Jan 22, 2025 17:18 JST

Mitsubishi Power Advances Thailand's Energy Development with Completion of 1,400MW Combined Cycle Hin Kong Power Plant
Jan 21, 2025 16:24 JST

DENSO Exhibits at Bharat Mobility Global Expo 2025, New Delhi
Jan 20, 2025 20:26 JST
 More Latest Release >>